Analyst Price Targets — DRTS
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| February 24, 2026 3:29 pm | Yi Chen | H.C. Wainwright | $12.00 | $7.50 | TheFly | Alpha Tau price target raised to $12 from $9 at H.C. Wainwright |
| September 3, 2025 10:51 am | Yi Chen | H.C. Wainwright | $9.00 | $3.59 | StreetInsider | H.C. Wainwright Reiterates Buy Rating on Alpha Tau Medical Ltd. (DRTS) |
| May 21, 2024 8:51 am | Jason Bednar | Piper Sandler | $7.00 | $2.91 | StreetInsider | Piper Sandler Reiterates Overweight Rating on Alpha Tau Medical Ltd. (DRTS) |
| November 23, 2022 6:21 am | — | Piper Sandler | $12.00 | $3.75 | Benzinga | Piper Sandler Maintains Overweight on Alpha Tau Medical, Lowers Price Target to $12 |
Latest News for DRTS
JERUSALEM, March 31, 2026 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd . (Nasdaq: DRTS, DRTSW) (“Alpha Tau”), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT® today announced that an abstract presenting results of two clinical trials in Jerusalem in patients with pancreatic cancer has been accepted for an oral presentation at Digestive Disease Week (DDW) 2026, the world's premier international…
Alpha Tau Medical pioneers localized alpha particle radiation for solid tumors, with its Alpha DaRT technology showing broad applicability and strong early efficacy. 2026 is pivotal for DRTS, with multiple clinical trial readouts expected in cSCC, pancreatic, GBM, and prostate cancers, potentially transforming its market standing. Despite a $42.3M operating loss in 2025 and no revenue, DRTS has about five to six…
JERUSALEM, March 16, 2026 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd . (Nasdaq: DRTS, DRTSW) ("Alpha Tau"), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT® today announced that CFO Raphi Levy will present at the Sidoti Virtual Small Cap Conference taking place on March 18-19, 2026.
- Tremendous activity in recent months, including receipt of Japanese marketing approval, the fifth parallel U.S. trial approval, data from pancreatic cancer trials presented at ASCO GI Symposium, and the first brain cancer treatment -
TOKYO--(BUSINESS WIRE)-- #cancer--Japan approves Alpha DaRT for head & neck cancer, becoming the first market outside Israel.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for DRTS.
U.S. House Trading
No House trades found for DRTS.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.